Cribado prenatal de la toxoplasmosis congénita

Medicina Clinica

Volumn 116, Issue 10, 2001, Pages 385-389

  Ortega Benito, José M ^a,b  

^a Kingston and Richmond Hlth Auth   (Spain)

^b NONE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

PROTOZOAL DNA; PROTOZOON ANTIBODY;

ANIMAL; ARTICLE; BLOOD; CONGENITAL TOXOPLASMOSIS; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; GENETICS; HUMAN; IMMUNOLOGY; NEWBORN; NEWBORN SCREENING; PRACTICE GUIDELINE; PREGNANCY; PRENATAL DIAGNOSIS; SEROLOGY; TOXOPLASMA;

ANIMALS; ANTIBODIES, PROTOZOAN; COST-BENEFIT ANALYSIS; DNA, PROTOZOAN; FEMALE; HUMANS; INFANT, NEWBORN; NEONATAL SCREENING; PRACTICE GUIDELINES; PREGNANCY; PRENATAL DIAGNOSIS; SEROLOGIC TESTS; TOXOPLASMA; TOXOPLASMOSIS, CONGENITAL;

EID: 0035901382     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0025-7753(01)71837-4     Document Type: Article

References (39)

1. Joyson DHM. Screening for toxoplasmosis in pregnancy. Contemp Rev Obstet Gynaecol 1990; 2: 1-7.
2. a ed.). Washington: American Public Health Association, 2000.
3. Hughes JM, Colley DG, López A, Dietz VJ, Wilson M, Navin TR et al. Preventing congenital toxoplasmosis. MMWR 2000; 49: 57-75.
4. Wilson JMG, Junger G. Principles and practice of screening for disease. Public Health Papers N.o 34. Ginebra: WHO, 1968.
5. Muñoz C, Izquierdo C, Parra J, Ginovart G, Margall N. Recommendation for prenatal screening for congenital toxoplasmosis. Eur J Clin Microbiol Infect Dis 2000; 19: 324-325.
6. Pujol-Riqué M, Quintó L, Danes C, Valls ME, Coll O, Jiménez de Anta MT. Seroprevalencia de la toxoplasmosis en mujeres en edad fértil (1992-1999). Med Clin (Barc) 2000; 115: 375-376.
7. Jaqueti J, Hernández-Garcia R, Nicolás D, Martínez-Hernández D, Navarro-Gallar F, Garcia-Esteban RJ. Serología frente a Toxoplasma gondii en mujeres gestantes. Evolución de las tasas de prevalencia a lo largo de cuatro años. Rev Clin Esp 1991; 188: 278-280
8. Ribes A, Saniger JM, Reche C, Segovia A, Peis JI, Cruz MC. Estudio serológico de las infecciones de transmisión vertical en las mujeres embarazadas en tres centros de salud en Jaén. Rev Esp Salud Pub 1996; 70: 313-318.
9. Guerra C, Fernández J. Seroprevalencia de Toxoplasma gondii en gestantes. Aten Primaria 1995; 3: 151-153.
10. Pumarola A, Salleras L, Vidal J, Canela J, Mas J, Jiménez del Anta MT et al. Prevalencia de anticuerpos contra Toxoplasma gondii, rubella, cytomegalovirus, y herpes simplex en mujeres gestantes de Cataluña. Enferm Infecc Microbiol Clin 1989; 7: 83-86.
11. Royal College of Obstetricians and Gynaecologists. Prenatal Screening for Toxoplasmosis in the UK. Report of a multidisciplinary working group. Londres: Royal College of Obstetricians and Gynaecologists, 1992.
12. Cook AJC, Gilbert RE, Buffolano W, Zufferey J, Petersen E, Jenum PA et al. Sources of toxoplasma infection in pregnant women: european multicentre case-control study. Br Med J 2000; 321: 142-147.
13. Lappalainen M, Sintonen H, Koskiniemi M, Hedman K, Hiilesma V, Ammala P. Cost-benefit analysis of screening for toxoplasmosis during pregnancy. Scand J Infect Dis 1995; 27: 265-272.
14. Bader TJ, Macones GA, Asch DA. Prenatal screening for toxoplasmosis Obstet Gynecol 1997; 90: 457-464.
15. Mittendorf R, Pryde P, Herschel M, Williams MA. Is routine antenatal toxoplasmosis screening justified in the United States? Statistical considerations in the application of medical screening tests. Clin Obstet Gynecol 1999; 42: 163-173.
16. Lebech M, Andersen O, Christensen NC, Hertel J, Nielsen HE, Peitersen B et al. Feasibility of neonatal screening for toxoplasma infection in the absence of prenatal treatment. Lancet 1999; 353: 1834-1837.
17. Petersen E, Eaton RB. Control of congenital infection with Toxoplasma gondii by neonatal screening based on detection of specific immunoglobulin M antibodies eluted from phenylketonuria filter-paper blood-spot samples. Acta Paediatr Suppl 1999; 88: 36-39.
18. Wallon M, Liou C, Garner P, Peyron F. Congenital toxoplasmosis: systematic review of evidence of efficacy of treatment in pregnancy. Br Med J 1999; 318: 1511-1514
19. Robert-Gangneux F, Gavinet MF, Ancelle T, Raymond J, Tourte-Schaefer C, Dupouy-Camet J. Value of prenatal diagnosis and early postnatal diagnosis of congenital toxoplasmosis: retrospective study of 110 cases. J Clin Microbiol 1999; 37: 2893-2898.
20. Ancelle T, Goulet V, Tirard-Fleury L, Baril C, DuMazaubrun P, Thuliez M et al. La toxoplasmose chez la femme enceinte en France en 1995. Bull Epidemiol Hebd 1996; 51: 227-229.
21. Dunn D. Wallon M. Peyron F, Petersen E, Peckham C, Gilbert R. Mother-to-child transmission of toxoplasmosis: risk estimates for clinical counselling. Lancet 1999; 353 1829-1833.
22. Hezard N, Marx-Chemla C. Foudrimer F, Villena I Quereux C, Leroux B et al. Prenatal diagnosis of congenital toxoplasmosis in 261 pregnancies. Prenat Diagn 1997; 17: 1047-1054.
23. Trojovsky A, Fast C, Lercher A, Pertl B, Gratzl R, Vander-Möse A et al. Konnatale toxoplasmose trotz Screening warum? Mitt Österr Ges Tropenmedizm und Parasitologie 1998; 20: 71-78.
24. Aspock H, Pollak A. Prevention of prenatal toxoplasmosis by serological screening of pregnant women in Austria. Scand J Infect Dis Suppl 1992; 84: 32-37.
25. Martin F. Congenital toxoplasmosis value of antenatal screening and current prenatal treatment. Trinity Student Med J 2000; 1: 46-51.
26. Instituto Nacional de Estadistica. Población 1998; 6. http://www.ine.es.
27. Guerina NG, Hsu HW, Meissner HC, Maguire JH, Lynfield R, Stechenberg B et al. Neonatal serologic screening and early treatment for congenital Toxoplasma gondii infection. The New England Toxoplasma Working Group. N Engl J Med 1994; 330: 1858-1863.
28. Foulon W, Villena I, Stray-Pedersen B, Decoster A, Lappalamen M, Pinon JM et al. Treatment of toxeplasmosis during pregnancy: a multicentre study of impact on foetal transmission and children's sequelae at age 1 year. Am J Obstet Gynecol 1999; 180: 410-415.
29. Foulon W, Pinon JM, Stray-Pedersen B, Pollak A, Lappalainen M, Decoster A et al. Prenatal diagnosis of congenital toxoplasmosis: a multicenter evaluation of different diagnostic parameters. Am J Obstet Gynecol 1999; 181: 843-847.
30. Lynfield R, Hsu HW, Guerina NG. Screening methods for congenital toxoplasma and risk of disease. Lancet 1999; 353: 1899-1900.
31. Schoen EJ, Black S, Cohen D. Screening for neonatal toxoplasmosis. N Engl J Med 1994; 331: 1458.
32. Gratzl R, Hayde M, Kohlhauser C, Hermon M, Burda G, Strobl W et al. Follow-up of infants with congenital toxoplasmosis detected by polymerase chain reaction analysis of amniotic fluid. Eur J Clin Microbiol 1998; 17: 853-858.
33. Wilson M, Remington JS, Clavet C, Varney G, Press C, Ware D, and the FDA Toxoplasmosis ad hoc Working Group. Evaluation of six commercial kits for detection of human immunoglobulin M antibodies to Toxoplasma gondii. J Clin Microbiol 1997; 35: 3112-3115.
34. Ortega-Benito JM. Los marcadores séricos en el diagnóstico prenatal del sindrome de Down: la prueba triple. Med Clin (Barc) 1995; 105: 264-268.
35. a ed.). Barcelona: Harcourt Pub., 2000.
36. Richards S, and R&D Directorate SWRHA. Prenatal diagnosis: amniocentesis or chorion villus sampling. Bristol NHS Executive South and West, Briefing Paper N.o 6, 1995.
37. Neassens A, Jenum P, Pollak A, Decoster A, Lappalamen M, Villena I et al. Diagnosis of congenital toxoplasmosis in the neonatal period: a multicenter evaluation. J Pediatr 1999; 135: 714-719.
38. Greig JR, Holliman R. Neonatal screening for Toxoplasma infection. Lancet 1999; 354: 1030.
39. Antenatal screening for toxoplasmosis in the UK [editorial]. Lancet 1990; 336: 346-348.